The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -102,835 |
| Depreciation | 23,731 |
| Amortization, including accretion and write-off of deferred financing costs | 9,955 |
| Deferred income taxes | 37,079 |
| Impairment of control devices assets | 21,628 |
| (gain) loss of equity method investee | 340 |
| Loss (gain) on sale of fixed assets | -146 |
| Share-based compensation expense | 4,801 |
| Excess tax deficiency related to share-based compensation expense | -475 |
| Accounts receivable, net | -17,341 |
| Inventories, net | -30,765 |
| Prepaid expenses and other assets | 7,489 |
| Accounts payable | -8,780 |
| Accrued expenses and other liabilities | 7,545 |
| Net cash provided by operating activities | 34,022 |
| Capital expenditures, including intangibles | 21,850 |
| Proceeds from sale of fixed assets | 399 |
| Investment in venture capital fund, net | 372 |
| Net cash used for investing activities | -21,823 |
| Revolving credit facility borrowings | 49,000 |
| Revolving credit facility payments | 73,191 |
| Proceeds from issuance of debt | 19,888 |
| Repayments of debt | 19,882 |
| Other financing costs | 777 |
| Repurchase of common shares to satisfy employee tax withholding | 340 |
| Net cash (used for) provided by financing activities | -25,302 |
| Effect of exchange rate changes on cash and cash equivalents | 7,523 |
| Net change in cash and cash equivalents | -5,580 |
| Cash and cash equivalents at beginning of period | 71,832 |
| Cash and cash equivalents at end of period | 66,252 |